Group 1 - The core viewpoint of the news is that Yuan Dong Bio has seen a significant increase in its stock price, rising by 5.47% to 55.30 CNY per share, with a trading volume of 150 million CNY and a turnover rate of 1.58%, leading to a total market capitalization of 9.762 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, and listed on September 2, 2020, is primarily engaged in the research, production, and sales of chemical raw materials and chemical drug formulations. The revenue composition is as follows: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - According to data from the top ten holdings of funds, a fund under Bank of China Securities has a significant position in Yuan Dong Bio. The Bank of China Securities Health Industry Mixed Fund (002938) held 146,000 shares in the third quarter, accounting for 5.07% of the fund's net value, ranking as the ninth largest holding. The estimated floating profit today is approximately 419,000 CNY [2] - The Bank of China Securities Health Industry Mixed Fund (002938) was established on September 7, 2016, with a current scale of 159 million CNY. Year-to-date returns are 41.95%, ranking 1861 out of 8155 in its category; the one-year return is 27.34%, ranking 3169 out of 8029; and since inception, the return is 138.44% [2]

Company Overview - Yuandong Biopharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On October 15, Yuandong's stock rose by 5.12%, reaching a price of 54.03 CNY per share, with a trading volume of 42.6 million CNY and a turnover rate of 0.46%. The total market capitalization is 9.538 billion CNY [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Yuandong Biopharmaceutical, with the Guotou Ruijin Healthcare Mixed A Fund (000523) holding 98,300 shares, accounting for 2.96% of the fund's net value, making it the seventh-largest holding. The estimated floating profit today is approximately 258,600 CNY [2] - The Guotou Ruijin Healthcare Mixed A Fund was established on February 25, 2014, with a latest scale of 121 million CNY. Year-to-date returns are 31.89%, ranking 2270 out of 8161 in its category; the one-year return is 25.9%, ranking 2959 out of 8015; and since inception, the return is 150.74% [2]

Company Overview - Yuan Dong Bio's stock price increased by 5.22% on September 1, reaching 68.95 CNY per share, with a trading volume of 1.07 billion CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 12.172 billion CNY [1] - The company has experienced a cumulative increase of 3.88% over the past three days [1] - Founded on June 1, 2009, and listed on September 2, 2020, Yuan Dong Bio specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Fund Holdings - According to data, one fund under Industrial Bank, the Xingye Healthcare A Fund (011466), holds a significant position in Yuan Dong Bio, with 699,200 shares, accounting for 7.46% of the fund's net value, making it the largest holding [2] - The fund has realized a floating profit of approximately 2.3913 million CNY today, with a floating profit of 1.7131 million CNY during the three-day increase [2] - Xingye Healthcare A Fund was established on March 8, 2021, with a current scale of 249 million CNY, achieving a year-to-date return of 33.5% and a one-year return of 41.06% [2]